Gunnar Henrik Heine/X
Jun 23, 2025, 13:27
Gunnar Henrik Heine: Apixaban Substantially Safer than Rivaroxan for Initial Treatment of VTE
Gunnar Henrik Heine, Professor of Internal Medicine at Saarland University, Editor of Nephrology Dialysis Transplantation (NDT), shared a post on X:
“RivaGate in DC at ISTH 2025. In COPRRA, apixaban was substantially safer than rivaroxan for initial (3 mo) treatment of VTE.
Lana Castellucci for this arguably most important DOAC study ever.”
More posts from ISTH 2025 on Hemostasis Today.
-
Oct 12, 2026, 07:08Larissa Chastain: Partnering to Transform Anticoagulation Management Through INR Self-Testing
-
Oct 12, 2026, 06:57Saiful Islam: Laboratory Spot Check – Microcytic Anemias and The Thalassemia Spectrum
-
Oct 12, 2026, 06:45Nick Lenamon: Stroke Awareness at Any Age Recognizing the Signs and Acting FAST
-
Oct 12, 2026, 04:45Aparna Korisetty: Upper GI Bleeding and Severe Anemia Secondary to Duodenal NET
-
Oct 12, 2026, 04:38Aya AlFakih: Why HbA1c Can Be High even When this Morning’s Glucose Looks Normal?
-
Oct 11, 2026, 22:40Bahram Alamdary Badlou: Platelets as First Responders in Hemostasis, Immunity, and Inflammation
-
Oct 11, 2026, 22:22Vipin Singh: New Publication on Hippo-YAP Signaling and Platelet Activation
-
Oct 11, 2026, 22:21Trygve Berge: New AFNOR Paper on AF-related Stroke in Norway
-
Oct 11, 2026, 22:09Omar Alomari: Our New Publication on Apixaban vs Rivaroxaban for VTE